ATE353655T1 - Myo-inositol hexaphosphat zur topischen verwendung - Google Patents

Myo-inositol hexaphosphat zur topischen verwendung

Info

Publication number
ATE353655T1
ATE353655T1 AT04798764T AT04798764T ATE353655T1 AT E353655 T1 ATE353655 T1 AT E353655T1 AT 04798764 T AT04798764 T AT 04798764T AT 04798764 T AT04798764 T AT 04798764T AT E353655 T1 ATE353655 T1 AT E353655T1
Authority
AT
Austria
Prior art keywords
myo
inositol hexaphosphate
topical use
development
treatment
Prior art date
Application number
AT04798764T
Other languages
English (en)
Inventor
Freixedas F Grases
Bestard J Perello
Amengual B Isern
Almirall R Prieto
Bauza A Costa
Original Assignee
Sanifit S L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit S L Lab filed Critical Sanifit S L Lab
Application granted granted Critical
Publication of ATE353655T1 publication Critical patent/ATE353655T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04798764T 2003-11-07 2004-11-03 Myo-inositol hexaphosphat zur topischen verwendung ATE353655T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302600A ES2232302B1 (es) 2003-11-07 2003-11-07 Myo-inositol hexafosfato para uso topico.

Publications (1)

Publication Number Publication Date
ATE353655T1 true ATE353655T1 (de) 2007-03-15

Family

ID=34566008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798764T ATE353655T1 (de) 2003-11-07 2004-11-03 Myo-inositol hexaphosphat zur topischen verwendung

Country Status (15)

Country Link
US (1) US20070066574A1 (de)
EP (1) EP1680128B1 (de)
JP (1) JP4786543B2 (de)
AT (1) ATE353655T1 (de)
BR (1) BRPI0415713A (de)
CA (1) CA2544963C (de)
CY (1) CY1106574T1 (de)
DE (1) DE602004004817T2 (de)
DK (1) DK1680128T3 (de)
ES (2) ES2232302B1 (de)
MX (1) MXPA06005043A (de)
PL (1) PL1680128T3 (de)
PT (1) PT1680128E (de)
SI (1) SI1680128T1 (de)
WO (1) WO2005044278A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
AU2003231157C1 (en) * 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
DK1863495T3 (en) * 2005-03-18 2015-04-20 Normoxys Inc CALCIUM AND SODIUM SALT OF MYO-INOSITOL 1.6: 2,3: 4,5 TRIPYROPHOSPHATE FOR CANCER TREATMENT
ES2272191B1 (es) * 2005-10-14 2008-04-01 Universitat De Les Illes Balears Utilizacion del fitato para el tratamiento del agua.
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
US20080312138A1 (en) * 2007-05-01 2008-12-18 Claude Nicolau Erythropoietin complementation or replacement
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
JP7758319B2 (ja) * 2018-03-15 2025-10-22 株式会社ラフィーネインターナショナル 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
CN113365636A (zh) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
IL318658A (en) 2022-07-29 2025-03-01 Sanifit Therapeutics S A IP4-4,6-Substituted Derivative Compounds for Use in the Treatment, Inhibition of Progression, and Prevention of Ectopic Calcification
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934002A (en) * 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US6359194B1 (en) * 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5536499A (en) * 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5614511A (en) * 1996-03-11 1997-03-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for treating itchy skin
JP3623430B2 (ja) * 2000-07-06 2005-02-23 築野ライスファインケミカルズ株式会社 抗酸化性組成物
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
EP1327443A1 (de) * 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Wirkstoffe zur Behandlung oder Prävention von Krankheiten, die durch eine reduzierte Expression des Klotho-Proteins verursacht wurden

Also Published As

Publication number Publication date
EP1680128A1 (de) 2006-07-19
DE602004004817T2 (de) 2007-11-22
US20070066574A1 (en) 2007-03-22
ES2232302A1 (es) 2005-05-16
BRPI0415713A (pt) 2006-12-19
JP4786543B2 (ja) 2011-10-05
PL1680128T3 (pl) 2007-07-31
PT1680128E (pt) 2007-05-31
ES2282920T3 (es) 2007-10-16
ES2232302B1 (es) 2006-08-01
DK1680128T3 (da) 2007-06-11
MXPA06005043A (es) 2007-03-15
CA2544963A1 (en) 2005-05-19
EP1680128B1 (de) 2007-02-14
DE602004004817D1 (de) 2007-03-29
WO2005044278A1 (en) 2005-05-19
CA2544963C (en) 2010-03-30
JP2007510710A (ja) 2007-04-26
CY1106574T1 (el) 2012-01-25
SI1680128T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA202091999A2 (ru) Применение ингибиторов dpp iv
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
ATE554800T1 (de) Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
ECSP077843A (es) Tratamiento o prevención del prurito
PT1220676E (pt) Prevencao do cancro colorrectal
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
BRPI0512316A (pt) métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ATE397935T1 (de) Pharmazeutische zubereitung zur applikation auf die haut mit einem gehalt an drospirenon
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1680128

Country of ref document: EP